CNS Lymphoma >  ASCO 2012 - CNS Lymphoma

Last update: 06/03/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

1. Central nervous system involvement in T-cell lymphomas: A single center experience. | 2012 ASCO Annual Meeting Abstracts
   
    

2. Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Children's Oncology Group. | 2012 ASCO Annual Meeting Abstracts
   
    

3. CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. | 2012 ASCO Annual Meeting Abstracts
   
    

4. Recurrent genetic alterations in primary central nervous system lymphoma of immunocompetent patients. | 2012 ASCO Annual Meeting Abstracts
   
    

5. Primary central nervous system lymphoma: The Cleveland Clinic experience. | 2012 ASCO Annual Meeting Abstracts
   
    

6. Primary CNS lymphoma: A review of clinicopathologic characteristics, therapy, and outcomes of 54 patients with primary CNS DLBCL. | 2012 ASCO Annual Meeting Abstracts
   
    

7. Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial. | 2012 ASCO Annual Meeting Abstracts
   
    

8. The natural history of intravascular lymphoma. | 2012 ASCO Annual Meeting Abstracts
   
    

9. High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma. | 2012 ASCO Annual Meeting Abstracts
   
    

10. Central nervous system lymphoma: Prognostic factors. | 2012 ASCO Annual Meeting Abstracts
    
     

11. Utility of iron oxide nanoparticles in the radiographic diagnosis of CNS lymphoma and inflammatory diseases. | 2012 ASCO Annual Meeting Abstracts
    
     

12. Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. | 2012 ASCO Annual Meeting Abstracts
    
     

13. Relationship of cognitive function, quality of life (QOL), and neuroimaging in primary CNS lymphoma (PCNSL) survivors. | 2012 ASCO Annual Meeting Abstracts
    
     

14. The natural history of intravascular lymphoma. | 2012 ASCO Annual Meeting Abstracts
    
     

15. Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL). | 2012 ASCO Annual Meeting Abstracts